Rapport Therapeutics (RAPP) Share-based Compensation (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Share-based Compensation data on file, last reported at $7.0 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $7.0 million, up 72.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 million (down 70.1% YoY), and the FY2025 annual result was $900000.0, down 91.21% from the prior year.
• Share-based Compensation grew to $7.0 million in Q1 2026 per RAPP's latest filing, from -$12.3 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $7.0 million in Q1 2026 and troughed at -$12.3 million in Q4 2025.
• A 4-year average of $1.7 million and a median of $2.8 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation surged 270.43% in 2024, then plunged 482.29% in 2025.
• A 4-year view of Share-based Compensation shows it stood at $998000.0 in 2023, then surged by 221.44% to $3.2 million in 2024, then sank by 482.29% to -$12.3 million in 2025, then jumped by 156.78% to $7.0 million in 2026.
• Business Quant data shows RAPP's Share-based Compensation at $7.0 million in Q1 2026, -$12.3 million in Q4 2025, and $4.7 million in Q3 2025.